Previous 10 | Next 10 |
2024-04-20 06:48:00 ET No risk, no reward. That's a fundamental part of investing. However, some stocks are less risky than others and still offer strong growth prospects. Three Motley Fool contributors think they've found relatively safe growth stocks you can buy and hold. Here's why t...
2024-04-19 04:30:00 ET Vertex Pharmaceuticals (NASDAQ: VRTX) is a growing pharmaceutical company with a robust cystic fibrosis (CF) business that generated nearly $10 billion in revenue last year. While there is still more room for the business to get bigger, Vertex is already at a ...
2024-04-18 08:49:58 ET More on Vertex Pharmaceuticals Vertex Pharmaceuticals: Alpine Accelerates Aspiration To Become Biotech Powerhouse Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement What Vertex Pharmaceuticals Is Getting With Acquisit...
2024-04-18 08:30:00 ET Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) continues to grab headlines. Over the past six months, the drugmaker has earned important regulatory approvals and made excellent clinical progress. But the company isn't stopping. Vertex just announced a mov...
– Rolling submission for suzetrigine moderate-to-severe acute pain NDA granted by FDA; first module submitted and on track to complete filing this quarter – – Successful completion of end-of-phase 2 FDA meeting for pain associated with diabetic peripheral neuropathy...
2024-04-15 16:46:49 ET More on bluebird bio, CRISPR Therapeutics, etc. Vertex Pharmaceuticals: Alpine Accelerates Aspiration To Become Biotech Powerhouse Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement What Vertex Pharmaceuticals Is Gett...
2024-04-15 09:15:00 ET Biotech acquisitions continue to abound this year. On April 10, Vertex Pharmaceuticals (NASDAQ: VRTX) announced it would purchase Alpine Immune Sciences (NASDAQ: ALPN) for $4.9 billion in cash in a deal that's set to close before the end of this quarte...
2024-04-13 05:29:00 ET The biotechnology industry is getting more attention than usual following a buyout offer for Alpine Immune Sciences (NASDAQ: ALPN) from Vertex Pharmaceuticals (NASDAQ: VRTX) . Vertex recently offered Alpine Immune Sciences $65 per share, or about $...
2024-04-12 07:20:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The positive momentum ...
2024-04-12 05:08:54 ET Summary Vertex Pharmaceuticals is the world's only provider of gene-based therapy for cystic fibrosis, with a $10 billion revenue business. The acquisition of Alpine Immune Sciences adds another therapy to Vertex's pipeline, potentially increasing the compan...
News, Short Squeeze, Breakout and More Instantly...
Vertex Pharmaceuticals Incorporated Company Name:
VRTX Stock Symbol:
NASDAQ Market:
Vertex Pharmaceuticals Incorporated Website:
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations Canada NewsWire -Approximately 200 people with certain rare CF mutations are now ...